依氟鸟氨酸 |
| 时间：2023-07-18 来源：化工号 作者：C6H12F2N2O2 |
| 中文名 | 依氟鸟氨酸
| | 英文名 | Eflornithine
| | 别名 | 依氟乌氨酸
依氟鸟氨酸
依氟鸟氨酸碱
二氟甲基鸟氨酸
依氟鸟氨酸碱盐酸盐
消旋型二氟甲基腈盐酸盐
依氟鸟氨酸碱(消旋体)
依氟鸟氨酸碱 (混旋体)
消旋型二氟甲基腈盐酸盐
DL-Α-二氟甲基鸟氨酸盐酸盐
DL-ALPHA-二氟甲基鸟氨酸盐酸盐
| | 英文别名 | Dfmo
DFMO
Ccris 3295
Brn 2250529
Eflornithine
Eflornithine base
DIFLUOROMETHYLORNITHINE
2-(difluoromethyl)ornithine
2-(difluoromethyl)-ornithin
DIFLUOROMETHYLORNITHINE(RG)
alpha-difluromethylornithine
H-DL-(A-DIFLUOROMETHYL)ORN-OH
α-Difluoromethyl-DL-ornithine
D,L-2-DIFLUOROMETHYLORNITHINE
alpha-difluoromethylornithine
H-.alpha.-Difluoro-Me-DL-Orn-OH
DL-α-Difluoromethylornithine hydrochloride
96020-91-6 (Mono-hydrochloride, monohydrate)
DL-2-(Difluoromethyl)-ornithinehydrochloride
alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid
DL-α-Difluoromethylornithine hydrochloride hydrate,2-(Difluoromethyl)ornithine hydrochloride hydrate, DFMO hydrochloride hydrate, Eflornithine hydrochloride hydrate
| | CAS | 67037-37-0
70052-12-9
| | 化学式 | C6H12F2N2O2
| | 分子量 | 182.17 | | InChI | InChI=1/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12) | | 密度 | 1.1800 (estimate) | | 熔点 | 138 °C | | 沸点 | 347.0±42.0 °C(Predicted) | | 闪点 | 163.7°C | | 蒸汽压 | 9.72E-06mmHg at 25°C | | 溶解度 | H2O: >10mg/mL, soluble | | 折射率 | 1.462 | | 酸度系数 | 1.22±0.44(Predicted) | | 存储条件 | Store at 0°C | | 外观 | solid | | 颜色 | white | | 体内研究 | Eflornithine is the only new molecule registered for the treatment of human African trypanosomiasis over the last 50 years. It is the drug used mainly as a back-up for melarsoprol refractory Trypanosoma brucei gambiense cases. In subjects with excessive, unwanted facial hair, eflornithine 15% cream is superior to placebo in reducing hair growth. After 24 weeks' treatment, 58% of eflornithine and 34% of placebo subjects have at least some improvement in facial hirsutism. The hair growth inhibitory activity of eflornithine is significantly enhanced when the eflornithine cream is applied onto a mouse skin area pretreated with microneedles. Treatment of coarctation hypertensive rats with eflornithine results in a normalization of the contractile intensity to KCI and norepinephrine and relaxations to acetylcholine by 14 days of hypertension. | | WGK Germany | 3 |
|
|
|
|
